Hib-DTP vaccine (Easyfour) (Panacea Biotec)(Hib-DTP vaccine (Easyfour) (Panacea Biotec)) - 在研适应症：白喉，嗜血杆菌感染，破伤风_专利_临床

概要

基本信息

药物类型

联合疫苗、预防性疫苗

别名

DTwPHib vaccine Panacea Biotec、Easy4、Easyfour Chiron Panacea

靶点-

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病其他疾病

在研适应症

白喉嗜血杆菌感染破伤风+ [1]

非在研适应症-

原研机构

Panacea Biotec Ltd.

在研机构

Panacea Biotec Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

印度 (2007-12-16),

百日咳

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 Hib-DTP vaccine (Easyfour) (Panacea Biotec) 相关的临床结果

登录后查看更多信息

100 项与 Hib-DTP vaccine (Easyfour) (Panacea Biotec) 相关的转化医学

登录后查看更多信息

100 项与 Hib-DTP vaccine (Easyfour) (Panacea Biotec) 相关的专利（医药）

登录后查看更多信息

1

项与 Hib-DTP vaccine (Easyfour) (Panacea Biotec) 相关的文献（医药）

1986-07-01·Archives of Pediatrics & Adolescent Medicine

Toddler Immunization Gap

Letter

作者: Le, C T ; Jones, M ; Schwarz, P

Sir .—In 1977 the National Childhood Immunization Initiative began, with the goal to raise immunization levels to greater than 90% of all vaccine-preventable diseases in the nation's children. Although the incidence of these infections has significantly declined in the United States, a substantial number of cases continue to be reported in the 1980s. 1 When the age and immunity status of affected children are known, it is clearly evident that at least half of the cases were potentially preventable. In 1982 and 1983, 68% of reported pertussis cases in children 3 months to 6 years old did not have adequate immunization with diphtheria-tetanuspertussis (DTP) vaccine. 2 In addition, 20.6% of all cases of measles in the first half of 1985 occurred in children 15 months to 4 years of age, and 69.2% of measles cases in preschool-age children were preventable. 3 While specific laws require proof of adequate immunity for

100 项与 Hib-DTP vaccine (Easyfour) (Panacea Biotec) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
白喉	印度	Panacea Biotec Ltd.	2008-01-01
嗜血杆菌感染	印度	Panacea Biotec Ltd.	2008-01-01
破伤风	印度	Panacea Biotec Ltd.	2007-12-19
百日咳	印度	Panacea Biotec Ltd.	2007-12-16